just a ramble for mg, page-27

mak,
Your exhaustion regarding dot joining is very understandable, most of the debates you were involved in were posted in 2010.
I, personally, stopped researching OBJ after I was satisfied with the proof of concept for our technologies which I was able to anticipate through my research and now has been is verified through announcements.



There is a personal limit of how long one can wait for success to set in.
You switched your main focus 2 years ago towards another transdermal company which had a bright spot a few months ago but fell back considerably since then.
In comparison though, it still did better in percentage terms than OBJ, so congratulations.



I would argue about the price sensitive comments in your post though.
The fact that P&G revealed their identity is price sensitive, maybe not to the ASX, but to every long term holder of OBJ shares.
It changed the entire game plan as it diversified the focus from GSK onto 2 major globals.

OBJ management has long ago chosen the path of partner supported research and development.
This comes increasingly at the price of silence surrounding their projects.

What is encouraging though is the fact that a growing number of European labs and Universities collaborate with OBJ's scientists, usually an indicator of outcourcing inhouse research and testing in partner controlled entities.
This only comes out of confidence towards an end result justifying the expense.



As long term shareholders we are nearing the period of commercial conclusion which can still drag a year out, in my humble opinion.
Within biotech timeframes, that is short to medium term, and illustrating the likely outlook of material events within that time frame.


Provided a positive outcome, approaching commercialisation would necessitate even tighter implementation of confidentiality clauses within the business model chosen by management.
It all comes down to have made up ones mind one way or the other, wether are nearing commercialisation or failure.

The silence of management allows for both, and this where FA based investment will always disagree with short term oriented investment styles.